Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and... see more

Bullboard (TSX:MSCL)

View:
Post by Drambueyon Apr 24, 2024 3:10pm

Post deleted SNOWFLAKES MANAGEMENT

So you deleted my post did it hit too close to home SNOWFLAKE MANAGEMENT?  Let me get this straight you roll back the stock 20 to one collect $1.4 million in salaries and the stock is trading at  ...more  
Comment by G1945Von Apr 24, 2024 7:13am

RE:You want to do what, AGAIN?

"you want to pass a resolution to roll this back again" Where is this coming from? G1945V
Post by beenthereon Mar 12, 2024 4:51pm

Sure Glad The Boys Moved To The TSX

Hate to think where we would be without that move!
Comment by beenthereon Jan 25, 2024 5:46pm

RE:Great day for Satellos

Yes for sure! It's definitely your lucky day!  lol Can I ask if you researched this company at all? Did you check the background of where this company came from? Did you check to see ...more  
Post by JohnnyChanginiton Jan 16, 2024 11:05am

Great day for Satellos

The TSX lising and prestigious award/recognition in one day! Soo glad I own this and just adding!
Post by G1945Von Jan 16, 2024 10:02am

BUSINESS WIRE

Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange G1945V
Post by Drambueyon Nov 21, 2023 4:51pm

15,000 gets you……..

Up 23% back to the price which the stock was trading at when they hired ICP Securities Inc.  Christmas bonuses all around lol
Post by Drambueyon Nov 01, 2023 4:55pm

What does $7,500 a month get you

Stock price down 23% since signing ICP Securities marketing services.   
Post by nozzpackon Aug 02, 2023 7:52am

Substantive News....Receives Orphan Drug Status !

  ORIGINAL: Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy Company also ...more  
Comment by london6erson Aug 01, 2023 4:29pm

RE:RE:RE:Ranked #1

Yes plus many other applications. 
Post by london6erson Jul 25, 2023 1:13pm

🤔

How can you replace fatty tissue with healthy muscle cells?
Comment by london6erson Jul 25, 2023 12:53pm

RE:RE:RE:Ranked #1

I agree but lots of the muscle is filled by scar tissue. What does this do? Replace scar tissue with functioning muscle cells? That's crazy if true..
Comment by nozzpackon May 23, 2023 1:41pm

RE:RE:Ranked #1

This will be a 25 bagger if  that small molecule drug with the potential to regenerate functional muscle is successful as it will have many advantages and benefits for patients muscular ...more  
Post by G1945Von May 17, 2023 9:43am

Satellos closes $55M Financing

Satellos Bioscience Closes $55M Financing to Support Development of its Lead Drug Candidate for Duchenne Muscular Dystrophy G1945V
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities